A Novel Transversion in the Intron 5 Donor Splice Junction of CYP2C19 and a Sequence Polymorphism in Exon 3 Contribute to the Poor Metabolizer Phenotype for the Anticonvulsant Drug S-Mephenytoin
Cytochrome P-450 (CYP) 2C19 is responsible for the metabolism of a number of therapeutic agents such as S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and imipramine. Genetic polymorphisms in this enzyme are responsible for the poor metabolizers (PM) of...
Saved in:
| Published in | The Journal of pharmacology and experimental therapeutics Vol. 290; no. 2; pp. 635 - 640 |
|---|---|
| Main Authors | , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
United States
01.08.1999
|
| Subjects | |
| Online Access | Get full text |
| ISSN | 0022-3565 |
| DOI | 10.1016/S0022-3565(24)34944-4 |
Cover
Loading…
| Abstract | Cytochrome P-450 (CYP) 2C19 is responsible for the metabolism of a number of therapeutic agents such as S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and imipramine. Genetic polymorphisms in this enzyme are responsible for the poor metabolizers (PM) of mephenytoin, which represent approximately 13-23% of Asians and 3-5% of Caucasians. Several polymorphisms contribute to this phenotype. We have isolated two new allelic variants that contribute to the PM phenotype in Caucasians. CYP2C19*7 contained a single T --> A nucleotide transversion in the invariant GT at the 5' donor splice site of intron 5. The second PM allele, CYP2C19*8, consisted of a T358C nucleotide transition in exon 3 that results in a Trp120Arg substitution. In a bacterial expression system, CYP2C198 protein exhibited a dramatic (approximately 90% and 70%) reduction in the metabolism of S-mephenytoin and tolbutamide, respectively, when compared with the wild-type CYP2C191B protein. Restriction fragment length polymerase chain reaction tests were developed to identify the new allelic variants. |
|---|---|
| AbstractList | Cytochrome P-450 (CYP) 2C19 is responsible for the metabolism of a number of therapeutic agents such as S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and imipramine. Genetic polymorphisms in this enzyme are responsible for the poor metabolizers (PM) of mephenytoin, which represent approximately 13-23% of Asians and 3-5% of Caucasians. Several polymorphisms contribute to this phenotype. We have isolated two new allelic variants that contribute to the PM phenotype in Caucasians. CYP2C19*7 contained a single T --> A nucleotide transversion in the invariant GT at the 5' donor splice site of intron 5. The second PM allele, CYP2C19*8, consisted of a T358C nucleotide transition in exon 3 that results in a Trp120Arg substitution. In a bacterial expression system, CYP2C198 protein exhibited a dramatic (approximately 90% and 70%) reduction in the metabolism of S-mephenytoin and tolbutamide, respectively, when compared with the wild-type CYP2C191B protein. Restriction fragment length polymerase chain reaction tests were developed to identify the new allelic variants. Cytochrome P-450 (CYP) 2C19 is responsible for the metabolism of a number of therapeutic agents such as S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and imipramine. Genetic polymorphisms in this enzyme are responsible for the poor metabolizers (PM) of mephenytoin, which represent approximately 13-23% of Asians and 3-5% of Caucasians. Several polymorphisms contribute to this phenotype. We have isolated two new allelic variants that contribute to the PM phenotype in Caucasians. CYP2C19*7 contained a single T --> A nucleotide transversion in the invariant GT at the 5' donor splice site of intron 5. The second PM allele, CYP2C19*8, consisted of a T358C nucleotide transition in exon 3 that results in a Trp120Arg substitution. In a bacterial expression system, CYP2C198 protein exhibited a dramatic (approximately 90% and 70%) reduction in the metabolism of S-mephenytoin and tolbutamide, respectively, when compared with the wild-type CYP2C191B protein. Restriction fragment length polymerase chain reaction tests were developed to identify the new allelic variants.Cytochrome P-450 (CYP) 2C19 is responsible for the metabolism of a number of therapeutic agents such as S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and imipramine. Genetic polymorphisms in this enzyme are responsible for the poor metabolizers (PM) of mephenytoin, which represent approximately 13-23% of Asians and 3-5% of Caucasians. Several polymorphisms contribute to this phenotype. We have isolated two new allelic variants that contribute to the PM phenotype in Caucasians. CYP2C19*7 contained a single T --> A nucleotide transversion in the invariant GT at the 5' donor splice site of intron 5. The second PM allele, CYP2C19*8, consisted of a T358C nucleotide transition in exon 3 that results in a Trp120Arg substitution. In a bacterial expression system, CYP2C198 protein exhibited a dramatic (approximately 90% and 70%) reduction in the metabolism of S-mephenytoin and tolbutamide, respectively, when compared with the wild-type CYP2C191B protein. Restriction fragment length polymerase chain reaction tests were developed to identify the new allelic variants. |
| Author | Ibeanu, Gordon C. Blaisdell, Joyce Ferguson, Ronald J. Wilkinson, Grant R. Ghanayem, Burhan I. Brøsen, Kim Benhamou, Simone Dayer, Pierre Goldstein, Joyce A. Bouchardy, Christine |
| Author_xml | – sequence: 1 givenname: Gordon C. surname: Ibeanu fullname: Ibeanu, Gordon C. – sequence: 2 givenname: Joyce surname: Blaisdell fullname: Blaisdell, Joyce – sequence: 3 givenname: Ronald J. surname: Ferguson fullname: Ferguson, Ronald J. – sequence: 4 givenname: Burhan I. surname: Ghanayem fullname: Ghanayem, Burhan I. – sequence: 5 givenname: Kim surname: Brøsen fullname: Brøsen, Kim – sequence: 6 givenname: Simone surname: Benhamou fullname: Benhamou, Simone – sequence: 7 givenname: Christine surname: Bouchardy fullname: Bouchardy, Christine – sequence: 8 givenname: Grant R. surname: Wilkinson fullname: Wilkinson, Grant R. – sequence: 9 givenname: Pierre surname: Dayer fullname: Dayer, Pierre – sequence: 10 givenname: Joyce A. surname: Goldstein fullname: Goldstein, Joyce A. |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/10411572$$D View this record in MEDLINE/PubMed |
| BookMark | eNqFkU9vFCEYhznU2D_6ETScjB5GGQZmlnjaTGutaXWTrQdPBNh3XMwMjMBs3H48P5nMthrjxRMBnt-P8D6n6Mh5Bwg9K8nrkpT1mzUhlBYVr_lLyl5VTDBWsCN08uf4GJ3G-I2QkrG6eoyOS8LKkjf0BP1c4o9-Bz2-DcrFHYRovcPW4bQFfOVSyDuOz73zAa_H3hrAHyZn0kz5DrdfVrQtBVZugxVew_cJXEZWvt8PPoxbG4e57OJHxivc-lxo9ZQAJ394YeVz7w0kpX1v7yDg1RacT_sRcJdvZmTpkjXe7aY-KpfweZi-4nVxA2Mm98lb9wQ96lQf4enDeoY-v7u4bd8X158ur9rldWEqwlPRCA20M4yrRsOGaU6VFjWjfGHYIs-MiErzRVMvNOm4MaJRqgbgzYbTuutEV52hF_e9Y_D5nzHJwUYDfa8c-CnKWghSCd5k8PkDOOkBNnIMdlBhL39PPQP8HjDBxxig-wuRs1F5MCpndZIyeTAqWc69_SdnbFKzixSU7f-T_gXPQ6ou |
| CitedBy_id | crossref_primary_10_1124_dmd_106_009548 crossref_primary_10_1124_dmd_108_026047 crossref_primary_10_1097_FPC_0b013e32834d4962 crossref_primary_10_1038_sj_tpj_6500044 crossref_primary_10_1124_dmd_110_037549 crossref_primary_10_3390_cancers17050863 crossref_primary_10_3109_00498254_2011_582893 crossref_primary_10_1016_j_arr_2010_06_001 crossref_primary_10_1016_j_thromres_2011_04_010 crossref_primary_10_1038_tpj_2008_14 crossref_primary_10_1517_17425255_2011_624513 crossref_primary_10_1124_dmd_116_073254 crossref_primary_10_1007_s12272_011_1103_2 crossref_primary_10_1111_j_1742_7843_2008_00222_x crossref_primary_10_1124_jpet_104_069872 crossref_primary_10_2133_dmpk_DMPK_11_RV_090 crossref_primary_10_1186_1472_6904_7_6 crossref_primary_10_1177_0091270008321811 crossref_primary_10_1517_17425255_4_4_413 |
| Cites_doi | 10.1097/00008571-199202000-00005 10.1016/0163-7258(89)90047-8 10.1093/nar/10.2.459 10.1097/00008571-199608000-00007 10.1021/bi00173a017 10.1182/blood.V76.5.1054.1054 10.1097/00007691-199302000-00002 10.1016/0079-6107(85)90004-5 10.1016/S0022-3565(24)37748-1 10.1016/S0090-9556(25)06696-6 10.1016/S0969-2126(01)00134-4 10.1016/0009-9236(95)90229-5 10.1007/BF00210743 10.1038/clpt.1985.196 10.1016/S0022-3565(24)36606-6 10.1038/clpt.1989.63 10.1097/00004850-198604000-00002 10.1097/00008571-199804000-00006 10.1111/j.1365-2125.1991.tb05542.x 10.1097/00008571-199510000-00007 10.1016/S0022-3565(24)37213-1 10.1016/S0076-6879(96)72025-6 10.1016/S0021-9258(20)82244-3 10.1097/00008571-199704000-00011 10.1016/S0021-9258(17)40694-6 10.1038/clpt.1991.4 10.1097/00008571-199402000-00004 10.1038/clpt.1989.11 10.1097/00008571-199702000-00008 10.1016/S0026-895X(25)09788-3 10.1016/0009-9236(95)90053-5 10.1074/jbc.271.21.12496 10.1038/clpt.1994.65 10.1097/00008571-199606000-00001 10.1006/abbi.1995.0013 10.1111/j.1365-2125.1991.tb05594.x 10.1006/abbi.1993.1506 |
| ContentType | Journal Article |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 |
| DOI | 10.1016/S0022-3565(24)34944-4 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Pharmacy, Therapeutics, & Pharmacology |
| EndPage | 640 |
| ExternalDocumentID | 10411572 10_1016_S0022_3565_24_34944_4 |
| Genre | Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S Journal Article |
| GrantInformation_xml | – fundername: NIGMS NIH HHS grantid: GM3B04 |
| GroupedDBID | --- -~X .55 .GJ 0R~ 18M 2WC 3O- 4.4 53G 5GY 5RE 5VS 8WZ A6W AALRI AAXUO AAYOK AAYXX ABCQX ABIVO ABJNI ABOCM ABSQV ACGFO ACGFS ACNCT ACVFH ADBBV ADCNI ADCOW AENEX AERNN AETEA AEUPX AFFNX AFOSN AFPUW AGFXO AI. AIGII AKBMS AKYEP ALMA_UNASSIGNED_HOLDINGS BAWUL BTFSW CITATION CS3 DIK DU5 E3Z EBS EJD F5P F9R FDB GX1 H13 HZ~ INIJC KQ8 L7B LSO M41 MJL MVM O9- OHT P2P R.V R0Z RHI ROL RPT TR2 UQL VH1 W8F WH7 WOQ X7M YBU YHG YQT ZGI ZXP AAJMC ADIYS AFHIN CGR CUY CVF ECM EIF NPM OK1 PKN RHF W2D 7X8 |
| ID | FETCH-LOGICAL-c305t-79be2fc45a7bed4b52ab964258c48349093b58768b0f5cc97aa6ee57d526ff9f3 |
| ISSN | 0022-3565 |
| IngestDate | Tue Aug 05 10:05:34 EDT 2025 Wed Feb 19 01:22:13 EST 2025 Tue Jul 01 05:27:54 EDT 2025 Thu Apr 24 23:10:29 EDT 2025 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 2 |
| Language | English |
| LinkModel | OpenURL |
| MergedId | FETCHMERGED-LOGICAL-c305t-79be2fc45a7bed4b52ab964258c48349093b58768b0f5cc97aa6ee57d526ff9f3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| PMID | 10411572 |
| PQID | 69903957 |
| PQPubID | 23479 |
| PageCount | 6 |
| ParticipantIDs | proquest_miscellaneous_69903957 pubmed_primary_10411572 crossref_primary_10_1016_S0022_3565_24_34944_4 crossref_citationtrail_10_1016_S0022_3565_24_34944_4 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 1900 |
| PublicationDate | 1999-08-01 |
| PublicationDateYYYYMMDD | 1999-08-01 |
| PublicationDate_xml | – month: 08 year: 1999 text: 1999-08-01 day: 01 |
| PublicationDecade | 1990 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States |
| PublicationTitle | The Journal of pharmacology and experimental therapeutics |
| PublicationTitleAlternate | J Pharmacol Exp Ther |
| PublicationYear | 1999 |
| References | Mount (10.1016/S0022-3565(24)34944-4_bib24) 1982; 10 de Morais (10.1016/S0022-3565(24)34944-4_bib11) 1995; 58 Daly (10.1016/S0022-3565(24)34944-4_bib8) 1996; 6 Benhamou (10.1016/S0022-3565(24)34944-4_bib5) 1997; 7 Skjelbo (10.1016/S0022-3565(24)34944-4_bib31) 1991; 49 10.1016/S0022-3565(24)34944-4_bib22 Ward (10.1016/S0022-3565(24)34944-4_bib35) 1989; 45 Ibeanu (10.1016/S0022-3565(24)34944-4_bib18) 1996; 271 Nielsen (10.1016/S0022-3565(24)34944-4_bib25) 1994; 55 Sanz (10.1016/S0022-3565(24)34944-4_bib28) 1989; 45 Goldstein (10.1016/S0022-3565(24)34944-4_bib14) 1994; 33 Sullivan-Klose (10.1016/S0022-3565(24)34944-4_bib32) 1996; 6 Adedoyin (10.1016/S0022-3565(24)34944-4_bib1) 1994; 4 Zhang (10.1016/S0022-3565(24)34944-4_bib40) 1992; 31 Andersson (10.1016/S0022-3565(24)34944-4_bib2) 1992; 2 Ward (10.1016/S0022-3565(24)34944-4_bib34) 1991; 31 Brøsen (10.1016/S0022-3565(24)34944-4_bib7) 1995; 5 Hasemann (10.1016/S0022-3565(24)34944-4_bib16) 1995; 2 Küpfer (10.1016/S0022-3565(24)34944-4_bib21) 1985; 38 Wedlund (10.1016/S0022-3565(24)34944-4_bib36) 1987; 15 Goldstein (10.1016/S0022-3565(24)34944-4_bib15) 1997; 7 Krawczak (10.1016/S0022-3565(24)34944-4_bib20) 1992; 90 Richardson (10.1016/S0022-3565(24)34944-4_bib27) 1995; 323 Suzuki (10.1016/S0022-3565(24)34944-4_bib33) 1998; 83 Bouhass (10.1016/S0022-3565(24)34944-4_bib6) 1990; 76 Balian (10.1016/S0022-3565(24)34944-4_bib3) 1995; 57 Ferguson (10.1016/S0022-3565(24)34944-4_bib12) 1998; 284 Mathews (10.1016/S0022-3565(24)34944-4_bib23) 1985; 45 de Morais (10.1016/S0022-3565(24)34944-4_bib9) 1994; 269 Ibeanu (10.1016/S0022-3565(24)34944-4_bib17) 1998; 8 Ibeanu (10.1016/S0022-3565(24)34944-4_bib19) 1998; 286 Wrighton (10.1016/S0022-3565(24)34944-4_bib38) 1993; 306 de Morais (10.1016/S0022-3565(24)34944-4_bib10) 1994; 46 Omura (10.1016/S0022-3565(24)34944-4_bib26) 1964; 239 Sarich (10.1016/S0022-3565(24)34944-4_bib29) 1997; 62 Sindrup (10.1016/S0022-3565(24)34944-4_bib30) 1993; 13 Goldstein (10.1016/S0022-3565(24)34944-4_bib13) 1996; 272 Xiao (10.1016/S0022-3565(24)34944-4_bib39) 1997; 281 Wilkinson (10.1016/S0022-3565(24)34944-4_bib37) 1989; 43 Baumann (10.1016/S0022-3565(24)34944-4_bib4) 1986; 1 |
| References_xml | – volume: 2 start-page: 25 year: 1992 ident: 10.1016/S0022-3565(24)34944-4_bib2 article-title: Polymorphic hydroxylation of S-mephenytoin and omeprazole metabolism in Caucasian and Chinese subjects. publication-title: Pharmacogenetics doi: 10.1097/00008571-199202000-00005 – volume: 43 start-page: 53 year: 1989 ident: 10.1016/S0022-3565(24)34944-4_bib37 article-title: Genetic polymorphism of S-mephenytoin hydroxylation. publication-title: Pharmacol Ther doi: 10.1016/0163-7258(89)90047-8 – volume: 10 start-page: 459 year: 1982 ident: 10.1016/S0022-3565(24)34944-4_bib24 article-title: A catalog of splice junction sequences. publication-title: Nucleic Acids Res doi: 10.1093/nar/10.2.459 – volume: 6 start-page: 341 year: 1996 ident: 10.1016/S0022-3565(24)34944-4_bib32 article-title: The role of the CYP2C9-Leu359 allelic variant in the tolbutamide polymorphism. publication-title: Pharmacogenetics doi: 10.1097/00008571-199608000-00007 – volume: 33 start-page: 1743 year: 1994 ident: 10.1016/S0022-3565(24)34944-4_bib14 article-title: Evidence that CYP2C19 is the major S-mephenytoin 4′-hydroxylase in humans. publication-title: Biochemistry doi: 10.1021/bi00173a017 – volume: 76 start-page: 1054 year: 1990 ident: 10.1016/S0022-3565(24)34944-4_bib6 article-title: A new mutation at IVS1 nt 2 (T→A) in β-thalassemia from Algeria. publication-title: Blood doi: 10.1182/blood.V76.5.1054.1054 – volume: 13 start-page: 11 year: 1993 ident: 10.1016/S0022-3565(24)34944-4_bib30 article-title: Pharmacokinetics of citalopram in relation to the sparteine and the mephenytoin oxidation polymorphisms. publication-title: Ther Drug Monit doi: 10.1097/00007691-199302000-00002 – volume: 45 start-page: 1 year: 1985 ident: 10.1016/S0022-3565(24)34944-4_bib23 article-title: The structure, function and evolution of cytochromes. publication-title: Prog Biophys Mol Biol doi: 10.1016/0079-6107(85)90004-5 – volume: 286 start-page: 1490 year: 1998 ident: 10.1016/S0022-3565(24)34944-4_bib19 article-title: Identification of new human CYP2C19 alleles (CYP2C19*6 and CYP2C19*2B) in a Caucasian poor metabolizer of mephenytoin. publication-title: J Pharmacol Exp Ther doi: 10.1016/S0022-3565(24)37748-1 – volume: 15 start-page: 277 year: 1987 ident: 10.1016/S0022-3565(24)34944-4_bib36 article-title: Pharmacogenetic association between the formation of 4-hydroxymephenytoin and a new metabolite of S-mephenytoin in man. publication-title: Drug Metab Dispos doi: 10.1016/S0090-9556(25)06696-6 – volume: 2 start-page: 41 year: 1995 ident: 10.1016/S0022-3565(24)34944-4_bib16 article-title: Structure and function of cytochromes P450: A comparative analysis of three structures. publication-title: Structure doi: 10.1016/S0969-2126(01)00134-4 – ident: 10.1016/S0022-3565(24)34944-4_bib22 – volume: 57 start-page: 662 year: 1995 ident: 10.1016/S0022-3565(24)34944-4_bib3 article-title: The hydroxylation of omeprazole correlates with S-mephenytoin metabolism: A population study. publication-title: Clin Pharmacol Ther doi: 10.1016/0009-9236(95)90229-5 – volume: 90 start-page: 1 year: 1992 ident: 10.1016/S0022-3565(24)34944-4_bib20 article-title: The mutational spectrum of single base-pair substitutions in mRNA splice junctions of human genes: Causes and consequences. publication-title: Hum Genet doi: 10.1007/BF00210743 – volume: 38 start-page: 414 year: 1985 ident: 10.1016/S0022-3565(24)34944-4_bib21 article-title: Stereo selective mephobarbital hydroxylation cosegregates with mephenytoin hydroxylation. publication-title: Clin Pharmacol Ther doi: 10.1038/clpt.1985.196 – volume: 281 start-page: 604 year: 1997 ident: 10.1016/S0022-3565(24)34944-4_bib39 article-title: Differences in the incidence of the CYP2C19 polymorphism affecting the S-mephenytoin phenotype in Chinese Han and Bai populations and identification of a new rare CYP2C19 mutant allele. publication-title: J Pharmacol Exp Ther doi: 10.1016/S0022-3565(24)36606-6 – volume: 62 start-page: 21 year: 1997 ident: 10.1016/S0022-3565(24)34944-4_bib29 article-title: The effect of omeprazole pretreatment on acetaminophen metabolism in rapid and slow metabolizers of S-mephenytoin. publication-title: Clin Pharmacol Ther – volume: 45 start-page: 495 year: 1989 ident: 10.1016/S0022-3565(24)34944-4_bib28 article-title: S-mephenytoin hydroxylation phenotypes in a Swedish population determined after coadministration with debrisoquine. publication-title: Clin Pharmacol Ther doi: 10.1038/clpt.1989.63 – volume: 1 start-page: 102 year: 1986 ident: 10.1016/S0022-3565(24)34944-4_bib4 article-title: Amitriptyline pharmacokinetics and clinical response. II. Metabolic polymorphism assessed by hydroxylation of debrisoquine and mephenytoin. publication-title: Int Clin Psychopharmacol doi: 10.1097/00004850-198604000-00002 – volume: 83 start-page: 199 year: 1998 ident: 10.1016/S0022-3565(24)34944-4_bib33 article-title: A new compound heterozygous mutation (W17X, 436 + 5G→T) in the cytochrome P450c17 gene causes 17α-hydroxylase/17,20-lyase deficiency. publication-title: J Clin Endocrinol Metab – volume: 8 start-page: 129 year: 1998 ident: 10.1016/S0022-3565(24)34944-4_bib17 article-title: An additional defective allele, CYP2C19*5, contributes to the S-mephenytoin poor metabolizer phenotype in Caucasians. publication-title: Pharmacogenetics doi: 10.1097/00008571-199804000-00006 – volume: 31 start-page: 350 year: 1992 ident: 10.1016/S0022-3565(24)34944-4_bib40 article-title: Limitation to the use of urinary S/R-mephenytoin ratio in pharmacogenetic studies. publication-title: Br J Clin Pharmacol doi: 10.1111/j.1365-2125.1991.tb05542.x – volume: 5 start-page: 312 year: 1995 ident: 10.1016/S0022-3565(24)34944-4_bib7 article-title: A multifamily study on the relationship between CYP2C19 genotype and S-mephenytoin oxidation phenotype. publication-title: Pharmacogenetics doi: 10.1097/00008571-199510000-00007 – volume: 284 start-page: 356 year: 1998 ident: 10.1016/S0022-3565(24)34944-4_bib12 article-title: A new genetic defect in human CYP2C19: Mutation of the initiation codon is responsible for poor metabolism of S-mephenytoin. publication-title: J Pharmacol Exp Ther doi: 10.1016/S0022-3565(24)37213-1 – volume: 272 start-page: 210 year: 1996 ident: 10.1016/S0022-3565(24)34944-4_bib13 article-title: Genetic tests which identify the principle defects in CYP2C19 responsible for the polymorphism in mephenytoin metabolism. publication-title: Methods Enzymol doi: 10.1016/S0076-6879(96)72025-6 – volume: 239 start-page: 2370 year: 1964 ident: 10.1016/S0022-3565(24)34944-4_bib26 article-title: The carbon monoxide-binding pigment of liver microsomes. publication-title: J Biol Chem doi: 10.1016/S0021-9258(20)82244-3 – volume: 7 start-page: 157 year: 1997 ident: 10.1016/S0022-3565(24)34944-4_bib5 article-title: Lung cancer risk in relation to mephenytoin hydroxylation activity. publication-title: Pharmacogenetics doi: 10.1097/00008571-199704000-00011 – volume: 269 start-page: 15419 year: 1994 ident: 10.1016/S0022-3565(24)34944-4_bib9 article-title: The major genetic defect responsible for the polymorphism of S-mephenytoin in humans. publication-title: J Biol Chem doi: 10.1016/S0021-9258(17)40694-6 – volume: 49 start-page: 18 year: 1991 ident: 10.1016/S0022-3565(24)34944-4_bib31 article-title: The mephenytoin oxidative polymorphism is partially responsible for the N-demethylation of imipramine. publication-title: Clin Pharmacol Ther doi: 10.1038/clpt.1991.4 – volume: 4 start-page: 27 year: 1994 ident: 10.1016/S0022-3565(24)34944-4_bib1 article-title: Stereoselective disposition of hexobarbital and its metabolites: Relationship to the S-mephenytoin polymorphism in Caucasian and Chinese subjects. publication-title: Pharmacogenetics doi: 10.1097/00008571-199402000-00004 – volume: 45 start-page: 72 year: 1989 ident: 10.1016/S0022-3565(24)34944-4_bib35 article-title: Propranolol’s metabolism is determined by both mephenytoin and debrisoquine hydroxylase activities. publication-title: Clin Pharmacol Ther doi: 10.1038/clpt.1989.11 – volume: 7 start-page: 59 year: 1997 ident: 10.1016/S0022-3565(24)34944-4_bib15 article-title: Frequencies of the defective CYP2C19 alleles responsible for the mephenytoin poor metabolizer phenotype in various Oriental, Caucasian, Saudi Arabian and American Black populations. publication-title: Pharmacogenetics doi: 10.1097/00008571-199702000-00008 – volume: 46 start-page: 594 year: 1994 ident: 10.1016/S0022-3565(24)34944-4_bib10 article-title: Identification of a new genetic defect responsible for the polymorphism of S-mephenytoin metabolism in Japanese. publication-title: Mol Pharmacol doi: 10.1016/S0026-895X(25)09788-3 – volume: 58 start-page: 404 year: 1995 ident: 10.1016/S0022-3565(24)34944-4_bib11 article-title: Genetic analysis of the S-mephenytoin polymorphism in a Chinese population. publication-title: Clin Pharmacol Ther doi: 10.1016/0009-9236(95)90053-5 – volume: 271 start-page: 12496 year: 1996 ident: 10.1016/S0022-3565(24)34944-4_bib18 article-title: Identification of residues 99, 220, and 221 of human cytochrome P450 2C19 as key determinants of omeprazole hydroxylase activity. publication-title: J Biol Chem doi: 10.1074/jbc.271.21.12496 – volume: 55 start-page: 518 year: 1994 ident: 10.1016/S0022-3565(24)34944-4_bib25 article-title: Single-dose kinetics of clomipramine: Relationship to the sparteine/debrisoquine and S-mephenytoin oxidation polymorphisms. publication-title: Clin Pharmacol Ther doi: 10.1038/clpt.1994.65 – volume: 6 start-page: 193 year: 1996 ident: 10.1016/S0022-3565(24)34944-4_bib8 article-title: Nomenclature for human CYP2D6 alleles. publication-title: Pharmacogenetics doi: 10.1097/00008571-199606000-00001 – volume: 323 start-page: 87 year: 1995 ident: 10.1016/S0022-3565(24)34944-4_bib27 article-title: A universal approach to the expression of human and rabbit cytochrome P450 of the 2C subfamily in Escherichia coli. publication-title: Arch Biochem Biophys doi: 10.1006/abbi.1995.0013 – volume: 31 start-page: 689 year: 1991 ident: 10.1016/S0022-3565(24)34944-4_bib34 article-title: The activation of the biguanide antimalarial proguanil co-segregates with the mephenytoin oxidation polymorphism: A panel study. publication-title: Br J Clin Pharmacol doi: 10.1111/j.1365-2125.1991.tb05594.x – volume: 306 start-page: 240 year: 1993 ident: 10.1016/S0022-3565(24)34944-4_bib38 article-title: Isolation and characterization of human liver cytochrome P450 2C19: Correlation between 2C19 and S-mephenytoin 4′-hydroxylation. publication-title: Arch Biochem Biophys doi: 10.1006/abbi.1993.1506 |
| SSID | ssj0014463 |
| Score | 1.9625676 |
| Snippet | Cytochrome P-450 (CYP) 2C19 is responsible for the metabolism of a number of therapeutic agents such as S-mephenytoin, omeprazole, proguanil, certain... |
| SourceID | proquest pubmed crossref |
| SourceType | Aggregation Database Index Database Enrichment Source |
| StartPage | 635 |
| SubjectTerms | Alleles Anticonvulsants - metabolism Aryl Hydrocarbon Hydroxylases Cytochrome P-450 CYP2C19 Cytochrome P-450 Enzyme Inhibitors Cytochrome P-450 Enzyme System - genetics Escherichia coli - genetics Escherichia coli - metabolism European Continental Ancestry Group Exons France Genotype Humans Introns Lung - enzymology Mephenytoin - metabolism Mixed Function Oxygenases - antagonists & inhibitors Mixed Function Oxygenases - genetics Mutagenesis, Site-Directed Phenotype Plasmids - genetics Polymerase Chain Reaction Polymorphism, Restriction Fragment Length Reverse Transcriptase Polymerase Chain Reaction |
| Title | A Novel Transversion in the Intron 5 Donor Splice Junction of CYP2C19 and a Sequence Polymorphism in Exon 3 Contribute to the Poor Metabolizer Phenotype for the Anticonvulsant Drug S-Mephenytoin |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/10411572 https://www.proquest.com/docview/69903957 |
| Volume | 290 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3bbtNAEF2F8sIL4k64zgNUINelXa8v-5hG0IIEikQrlSdrba9LqsSOErsi_Ty-h49gdtdrO4KKy4tl-bIb5Rx7ZsdnZgh5gU5wFvo5d6Ms4C4TaeDyJPBcLqjn7eehiHTTvo-fgqMT9uHUPx0MfvRUS3WV7KaXv80r-R9U8RjiqrJk_wHZdlA8gPuIL24RYdz-FcYjpygvpFKLo8G5MJEvK1ycKgl64fhOVhbl0lmp79TSOUczZn3E8ZcJHe9zU67VsZpq1bZhPS_x71ftM1RBkW94uWc07ao5lrTu6qLEceeyQhrNppdy6Si5WKljula7iLBNla69nq1w18mW9Znz2Z1rYdm6Kpuq3-cdY3v-8aIrqm1qRG00I-jljbWrgveJFEWtI_1d8PdgJqarzGp5euHzs9rWFugOH34VhVhL_YwcNAHlrMkR5K0gbzNFwTShsK95atqSNnymvZd2YAqm_GJMTFxj1Y6GLj9lL9E_Ypwxk5vUI9lirlmGy1tVv4h29rVVPdpT18h1iosa1W_j8LQVJKmFudfWtsfpunyzN91veEXZ62Z-Ve-2GXHTqbpipaQ9puNb5GYDJYwMb2-TgSzukO2JgXW9A8c9CHdgGyY9wO-S7yPQ5IY-uWFaACIPhtzggyY3GHKDJTeUOTTkBiQOCLDkhj651WCK3OBBR26oSj2DIjf0yA0tuQHJrS_ZJDcocsMGue-Rk3dvj8dHbtNwxE3R7FVuyBNJ85T5IkxkxhKfioTjAt2PUhVz53vcS3x0H6JkL_fTlIdCBFL6YebTIM957t0nW0VZyIcEIqZaK2RoMRPOaMgF2jqJy41ciChMIzkkzCIWp001ftUUZhZ3skvEPFaYx5TFGvOYDclue9vClKP50w3PLR1iNBzqa6AoZFmv4gD9UPWRfkgeGJb0BjSsenTlmcfkRvfcPSFb1bKWT9E5r5JnmtM_AQXG5mM |
| linkProvider | Geneva Foundation for Medical Education and Research |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=A+novel+transversion+in+the+intron+5+donor+splice+junction+of+CYP2C19+and+a+sequence+polymorphism+in+exon+3+contribute+to+the+poor+metabolizer+phenotype+for+the+anticonvulsant+drug+S-mephenytoin&rft.jtitle=The+Journal+of+pharmacology+and+experimental+therapeutics&rft.au=Ibeanu%2C+G+C&rft.au=Blaisdell%2C+J&rft.au=Ferguson%2C+R+J&rft.au=Ghanayem%2C+B+I&rft.date=1999-08-01&rft.issn=0022-3565&rft.volume=290&rft.issue=2&rft.spage=635&rft_id=info:doi/10.1016%2Fs0022-3565%2824%2934944-4&rft_id=info%3Apmid%2F10411572&rft.externalDocID=10411572 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0022-3565&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0022-3565&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0022-3565&client=summon |